Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,724 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,600 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06431633 | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.(ARIAN) | recruiting | Phase 3 | 129 | Fundación GECPOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04380636 | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | active not recruiting | Phase 3 | 870 | Merck Sharp & Dohme LLCINDUSTRY |
| 26 |
| May 15, 2026 |
| clinicaltrials |
| NCT06284317 | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.(ADOPT-lung) | recruiting | Phase 3 | 290 | ETOP IBCSG Partners FoundationNETWORK | 10 | May 14, 2026 | clinicaltrials |
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(TROPION-Lung15) | recruiting | Phase 3 | 744 | AstraZenecaINDUSTRY | 27 | May 14, 2026 | clinicaltrials |
| NCT06486142 | EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study(ERIS) | recruiting | Phase 3 | 200 | Region SkaneOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06437977 | Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)(neoR-TORCH) | recruiting | Phase 3 | 478 | Shanghai Chest HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07376382 | A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC(SYNSTAR-02) | not yet recruiting | Phase 3 | 680 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | May 13, 2026 | clinicaltrials |
| NCT04746924 | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | terminated | Phase 3 | 669 | BeiGeneINDUSTRY | 19 | May 12, 2026 | clinicaltrials |
| NCT05918302 | Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.(LEVEL) | recruiting | Phase 3 | 170 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 4 | May 12, 2026 | clinicaltrials |
| NCT03607539 | Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC | completed | Phase 3 | 397 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT05870319 | A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients | active not recruiting | Phase 3 | 376 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06448312 | A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 406 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05089734 | Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)(EVOKE-01) | active not recruiting | Phase 3 | 603 | Gilead SciencesINDUSTRY | 20 | May 7, 2026 | clinicaltrials |
| NCT04564157 | New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy(NADIM-ADJUVANT) | active not recruiting | Phase 3 | 210 | Fundación GECPOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06616584 | Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | recruiting | Phase 2 / Phase 3 | 378 | SWOG Cancer Research NetworkNETWORK | 1 | May 5, 2026 | clinicaltrials |
| NCT04585490 | Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC | recruiting | Phase 3 | 48 | Maximilian DiehnOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06930794 | A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive(KUNPENG-3) | recruiting | Phase 3 | 300 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07560358 | Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 204 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06117774 | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)(DeLLphi-306) | active not recruiting | Phase 3 | 404 | AmgenINDUSTRY | 27 | Apr 29, 2026 | clinicaltrials |
| NCT05522660 | Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer(USZ-STRIKE) | recruiting | Phase 3 | 180 | ETOP IBCSG Partners FoundationNETWORK | 5 | Apr 27, 2026 | clinicaltrials |
| NCT06281964 | Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.(KANNON-2) | enrolling by invitation | Phase 3 | 327 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05687266 | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations(AVANZAR) | active not recruiting | Phase 3 | 1,350 | AstraZenecaINDUSTRY | 23 | Apr 22, 2026 | clinicaltrials |
| NCT06838273 | A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04) | recruiting | Phase 3 | 720 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05633602 | Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study | active not recruiting | Phase 3 | 838 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06382129 | A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | active not recruiting | Phase 3 | 698 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06500026 | A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) | active not recruiting | Phase 3 | 722 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02468024 | JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer(STABLE-MATES) | recruiting | Phase 3 | 272 | University of Texas Southwestern Medical CenterOTHER | 4 | Apr 16, 2026 | clinicaltrials |
| NCT01630733 | A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer(ENSPIRIT) | completed | Phase 3 | 664 | Achieve Life SciencesINDUSTRY | 14 | Apr 15, 2026 | clinicaltrials |
| NCT03637816 | Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 / Phase 3 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06141070 | Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease(ANDROMEDA) | recruiting | Phase 3 | 240 | Vastra Gotaland RegionOTHER_GOV | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06564324 | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients | recruiting | Phase 3 | 194 | Nuvation Bio Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05445791 | Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations(METLUNG) | recruiting | Phase 3 | 312 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05852990 | Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC | recruiting | Phase 3 | 28 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06810375 | Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery | recruiting | Phase 3 | 120 | George Washington UniversityOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06928389 | Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer(NSCLC) | recruiting | Phase 3 | 536 | AkesoINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06545747 | Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI | recruiting | Phase 3 | 490 | Sun Yat-sen UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07481786 | Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases | recruiting | Phase 3 | 220 | Sun Yat-sen UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04256421 | A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer(SKYSCRAPER-02) | completed | Phase 3 | 490 | Hoffmann-La RocheINDUSTRY | 23 | Apr 3, 2026 | clinicaltrials |
| NCT06840704 | Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer(Relief) | recruiting | Phase 3 | 121 | Hunan Cancer HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06430866 | Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)(Eucalyptus) | active not recruiting | Phase 3 | 163 | AmgenINDUSTRY | 18 | Apr 1, 2026 | clinicaltrials |
| NCT07015892 | Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial(ESCALADOR) | recruiting | Phase 3 | 300 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04129502 | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | active not recruiting | Phase 3 | 354 | TakedaINDUSTRY | 24 | Mar 30, 2026 | clinicaltrials |
| NCT06123754 | Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC | recruiting | Phase 3 | 390 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07477808 | Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 116 | Hunan Province Tumor HospitalOTHER | 0 | Mar 23, 2026 | clinicaltrials |
| NCT06671379 | A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC | active not recruiting | Phase 3 | 498 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02973789 | Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | completed | Phase 3 | 291 | NovoCure GmbHINDUSTRY | 18 | Mar 18, 2026 | clinicaltrials |
| NCT04379635 | Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 3 | 453 | BeiGeneINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06726265 | Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) | active not recruiting | Phase 3 | 756 | Immutep S.A.S.INDUSTRY | 27 | Mar 18, 2026 | clinicaltrials |
| NCT02504372 | Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)(PEARLS) | completed | Phase 3 | 1,177 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 18, 2026source: clinicaltrials